In late 2026, the industry is pivoting toward "Exosome-Based Neuro-Therapies." This year, a radical new class of "Messenger Vesicles" is being used to deliver growth factors directly across the blood-brain barrier to repair damaged neurons in patients with Parkinson's and spinal cord injuries. Using data from these "Synaptic-Repair" studies, the Red Biotechnology Market is proving that the...
0 Commentarios
0 Acciones
854 Views
0 Vista previa
English
Arabic
French
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek